4 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 7 Phase 2, 2 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Recruiting 2, Unknown 2, Completed 1, Terminated 1, Withdrawn 1 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Invasive Lobular Breast Carcinoma: new trials by email Literature Review of Invasive Lobular Breast Carcinoma trials Research Report on Invasive Lobular Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Disease Extent in Stage IV Lobular Carcinoma: the Aid of Imaging and Liquid Biopsy Analyses whole body diffusion weighted MRI, ctDNA - Invasive Lobular Breast Carcinoma | Not applicable | Not yet recruiting | KU Leuven | 43 | 2026-07-01 | 2026-06-09 |
| [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [68Ga]BED003 - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-06-30 | 2026-09-15 |
| [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications [18F]FPyQCP - Colorectal Cancer, Epithelial Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Blue Earth Diagnostics | 71 | 2026-02-19 | 2026-10-28 |
| Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System managing Male Breast Cancer Patients at Methodist Health System - Ductal Carcinoma in Situ, Invasive Lobular Breast Carcinoma | Completed | Methodist Health System | 8 | 2023-05-04 | 2026-03-27 | |
| Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Entrectinib, Letrozole, Goserelin - Invasive Lobular Breast Carcinoma, ER+ Breast Cancer | Phase 2 | Unknown | Jules Bordet Institute | 65 | 2021-01-14 | 2024-12-04 |
| [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma [18F]Fluoroestradiol (FES) PET/CT - Invasive Lobular Breast Carcinoma | Phase 2 | Terminated | University of Utah | 44 | 2020-12-11 | 2025-05-18 |
| Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Radiomic, pathomic, and clinical markers - Breast Cancer, Invasive Ductal Breast Carcinoma | Unknown | Sunnybrook Health Sciences Centre | 800 | 2018-08-30 | 2019-07-16 | |
| Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery fulvestrant, anastrozole - Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1473 | 2014-02-27 | 2026-06-05 |
| Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy Behavioral dietary intervention, Therapeutic conventional surgery, Radiation therapy - Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma | Not applicable | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 38 | 2013-03-08 | 2025-06-06 |
| "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer" Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab - Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma | Phase 2 | Unknown | Auxilio Mutuo Cancer Center | 60 | 2011-03-01 | 2012-07-16 |
| Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer External beam radiation therapy - Inflammatory Breast Cancer, Invasive Ductal Breast Carcinoma | Phase 2 | Completed | Rutgers, The State University of New Jersey | 69 | 2010-12-21 | 2023-04-20 |
| Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer external beam radiation therapy, questionnaire administration, therapeutic conventional surgery - Ductal Breast Carcinoma in Situ, Estrogen Receptor-negative Breast Cancer | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2010-02-01 | 2011-12-08 | |
| Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery - Central Nervous System Metastases, Invasive Ductal Breast Carcinoma | Completed | University of Chicago | 4 | 2009-06-15 | 2024-07-31 |
Carcinoma, Lobular (13) · Breast Neoplasms (6) · Carcinoma, Ductal, Breast (6) · Breast Carcinoma In Situ (3) · Carcinoma, Intraductal, Noninfiltrating (3) · Breast Neoplasms, Male (2) · Carcinoma, Ovarian Epithelial (2) · Colorectal Neoplasms (2) · Inflammatory Breast Neoplasms (2) · Stomach Neoplasms (2) · Brain Neoplasms (1)
Adenocarcinoma (13) · Breast Diseases (13) · Carcinoma (13) · Neoplasms (13) · Neoplasms by Histologic Type (13) · Neoplasms by Site (13) · Neoplasms, Ductal, Lobular, and Medullary (13) · Neoplasms, Glandular and Epithelial (13) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Breast Neoplasms (7) · Carcinoma, Ductal (6) · Carcinoma in Situ (5) · Adnexal Diseases (2) · Breast Carcinoma In Situ (2)
Anastrozole (1) · Bevacizumab (1) · Capecitabine (1) · Counseling (1) · Cyclophosphamide (1) · Docetaxel (1) · Epirubicin (1) · Fluorine-18 (1) · Fulvestrant (1) · Goserelin (1) · Letrozole (1) · Neoadjuvant Therapy (1) · Radiation (1) · Radiomics (1) · Radiosurgery (1)
Blue Earth Diagnostics (2) · Alliance for Clinical Trials in Oncology (1) · Auxilio Mutuo Cancer Center (1) · Case Comprehensive Cancer Center (1) · Jules Bordet Institute (1) · KU Leuven (1) · Methodist Health System (1) · Rutgers, The State University of New Jersey (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Sunnybrook Health Sciences Centre (1) · University of Chicago (1) · University of Utah (1)
United States (8) · Puerto Rico (2) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Netherlands (1)
Philippe Aftimos, MD (2) · Bruce Haffty, MD (1) · Cynthia Ma, MD, PhD (1) · Elia Biganzoli, PHD (1) · Fang-I Lu, MD, FRCPC (1) · Fernando Cabanillas, MD (1) · Hans Wildiers, MD/PHD (1) · Jeffrey Yap, PhD (1) · Kasia Jerzak, M.Sc., MD (1) · Nicole Simone, MD (1) · Steven Chmura (1) · Steven Rowe, MD (1) · William Chen, MD (1) · William T. Tran, MRT(T), PhD (1)
PMID 28045625, PMID 35119530, PMID 35695563, PMID 36919879, PMID 38236590
2025 (1), P30CA056036 (1), P30CA072720 (1), U10CA031946 (1)